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Background: Cidofovir (CDV) proved efficacious in treatment of human papillomaviruses (HPVs) hyperplasias.
Antiproliferative effects of CDV have been associated with apoptosis induction, S-phase accumulation, and
increased levels of tumor suppressor proteins. However, the molecular mechanisms for the selectivity and antitumor
activity of CDV against HPV-transformed cells remain unexplained.
Methods: We evaluated CDV drug metabolism and incorporation into cellular DNA, in addition to whole genome
gene expression profiling by means of microarrays in two HPV+ cervical carcinoma cells, HPV- immortalized
keratinocytes, and normal keratinocytes.
Results: Determination of the metabolism and drug incorporation of CDV into genomic DNA demonstrated a
higher rate of drug incorporation in HPV+ tumor cells and immortalized keratinocytes compared to normal
keratinocytes. Gene expression profiling clearly showed distinct and specific drug effects in the cell types
investigated. Although an effect on inflammatory response was seen in all cell types, different pathways were
identified in normal keratinocytes compared to immortalized keratinocytes and HPV+ tumor cells. Notably, Rho
GTPase pathways, LXR/RXR pathways, and acute phase response signaling were exclusively activated in
immortalized cells. CDV exposed normal keratinocytes displayed activated cell cycle regulation upon DNA damage
signaling to allow DNA repair via homologous recombination, resulting in genomic stability and survival. Although
CDV induced cell cycle arrest in HPV- immortalized cells, DNA repair was not activated in these cells. In contrast,
HPV+ cells lacked cell cycle regulation, leading to genomic instability and eventually apoptosis.
Conclusions: Taken together, our data provide novel insights into the mechanism of action of CDV and its
selectivity for HPV-transformed cells. The proposed mechanism suggests that this selectivity is based on the inability
of HPV+ cells to respond to DNA damage, rather than on a direct anti-HPV effect. Since cell cycle control is
deregulated by the viral oncoproteins E6 and E7 in HPV+ cells, these cells are more susceptible to DNA damage
than normal keratinocytes. Our findings underline the therapeutic potential of CDV for HPV-associated malignancies
as well as other neoplasias.
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Human papillomaviruses (HPVs) are small double-
stranded DNA viruses with a strict epithelial tropism.
HPVs infect either mucosal or cutaneous surfaces causing
a variety of diseases ranging from benign warts (low-
risk types) to malignant neoplasms, including cervical
carcinoma and other anogenital cancers (high-risk types)
[1]. The virus infects cells in the basal layer of stratified
squamous epithelia and viral replication shows both tem-
poral and spatial regulation of viral protein expression. Ex-
cept for E1 (replicative helicase) and E2 (DNA-binding
regulatory protein), HPV completely relies on the cellular
DNA synthesis machinery for its genome replication [2].
Development of HPV-induced cancerous lesions is often
accompanied by partial integration of the viral genome in
the host cell DNA, resulting in conservation and stabilized
expression of E6 and E7 oncoproteins [3]. Other parts of
the viral genome are usually either deleted or show a dis-
turbed expression [4]. Therefore, cell lines derived from
cervical carcinomas do not produce HPV virions and only
express the E6 and E7 oncoproteins [5,6].
These two viral oncogenes cooperate in cell transform-
ation and immortalization [7]. The E7 oncoprotein over-
rides the G1/S checkpoint of the cell cycle through
association with the retinoblastoma family of proteins
(pRb, p107 and p130). Via induction of their ubiquitin-
mediated proteolysis, and disruption of their association
with the E2f family of transcription factors, E7 activates
expression of several S-phase specific genes [8]. E7 also
alters cell cycle control through interactions with histone
deacetylases, cyclins and cyclin-dependent kinase inhibi-
tors (p21CIP1 and p27KIP1) that are important regulators
of growth arrest during epithelial differentiation [7]. As
a result of pRb degradation, other activities of this tumor
suppressor protein, such as DNA repair and maintenance
of genomic integrity, are also abrogated. E7 expression
causes stabilization and functional impairment of the
tumor suppressor protein p53 resulting in stimulation of
apoptosis. To counteract this, E6 proteins target p53, lead-
ing to ubiquitinylation and proteasomal degradation of
p53, preventing cell growth arrest and apoptosis [9]. E6
proteins also activate telomerase expression and regulate
the activities of PDZ domain-containing proteins and
tumor necrosis factor receptors. Both E6 and E7 induce
genomic instability and also target cytokine expression to
control cell proliferation and interferon responses [7].
HPV-related malignancies, other than cervical cancer,
have increased in the last years because of the higher
number of immunocompromised patients. Current treat-
ment modalities for HPV-associated anogenital hyper-
plasia rely on removal of the lesions and are often
mutilating, painful and associated with high recurrence
rates. New medical therapies, such as intralesional or
topical administration of cidofovir (CDV, VistideW), whichmaintain the anatomical integrity and sexual function of
the patients need to be further investigated. Cidofovir,
approved by the FDA for intravenous administration in
the therapy of cytomegalovirus retinitis in AIDS patients,
has a broad-spectrum anti-DNA virus activity, including
HPVs [10]. Its antiviral activity against viruses that encode
for their own DNA polymerases (herpes-, pox-, and adeno-
viruses) is based on a higher affinity of the active diphos-
phate metabolite (CDVpp) for viral DNA polymerases
compared to cellular DNA polymerases [10].
CDV can be used intravenously, intralesionally or topic-
ally. Systemic administration requires co-administration of
oral probenecid and intravenous hydration to prevent
nephrotoxicity. Topical cidofovir is a simple and usually
well-tolerated therapy with minimal, if any, side effects
(ulcerations at the site of affected mucosa but not on the
surrounding normal tissue). These local side effects, when
appearing, are self-healing and do not require cessation
of treatment. Despite the fact that HPVs do not encode
for their own DNA polymerase, off-label use of cidofovir
was effective in the treatment of high-risk HPV-associated
hyperplasia’s including, cervical [11,12], vulvar [13-15],
perianal [14], gingival and buccal [16], and hypopharyngeal
and esophageal [17] neoplasias.
In vitro, CDV has been shown to exert antiproliferative
effects against HPV-positive (HPV+) cervical carcinoma
cells, and to a lower extent against HPV-negative (HPV-)
immortalized cells [18]. The antiproliferative effect of
CDV was ascribed to apoptosis induction, accumulation
of cells in S-phase, and induction of p53, pRb and p21
protein expression [19,20]. A synergistic effect of CDV
and radiation in HPV+ cervical carcinoma cells [21] and
in head and neck squamous cell carcinoma cells [22] was
associated with p53 accumulation. The stromal-derived
factor 1 (SDF-1α)-stimulated invasiveness of HPV+ cells
was abrogated by CDV and this anti-metastatic action
was mediated by inhibition of E6/E7, CXCR4 and Rho/
ROCK signaling [23]. To explain the selectivity of CDV
for HPV-transformed cells, it was suggested that CDV
could be differentially metabolized in HPV16+ cells ver-
sus human keratinocytes [24]. However, the molecular
mechanisms underlying the selectivity of CDV for HPV
remain unexplained.
Gene expression profiling has proven successful in
identifying the mechanism of action of pharmaceutical
agents [25,26]. In this study, we evaluated gene expres-
sion changes following CDV treatment of different cell
types [including, two HPV+ cervical carcinoma cell lines
(SiHa and HeLa), an HPV- immortalized keratinocyte cell
line (HaCaT), and primary human keratinocytes (PHKs)]
to provide more insights into the mode of action and se-
lectivity of CDV. Furthermore, metabolic studies and
drug incorporation into genomic DNA were analyzed in
the four cell types.
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Antiviral compound
Cidofovir (CDV), obtained from Gilead Sciences (Foster
City, CA, USA), was prepared as 10 mg/ml solution in
PBS. [5-3H]-CDV (1 mCi/ml; specific activity: 26 Ci/mmol)
was synthesized by Moravek Biochemicals (Brea, CA,
USA), and stored at −20°C in ethanol/water 1:1.
Cell cultures
The following cell types were used: HPV16+ (SiHa) and
HPV18+ (HeLa) cervical carcinoma cell lines, HPV- hu-
man immortalized keratinocytes (HaCaT) and primary
human keratinocytes (PHKs). SiHa, HeLa and HaCaT
cells were maintained in Dulbecco’s modified Eagle’s
medium (GibcoW, Life Technologies™, Invitrogen, Belgium)
supplemented with 10% fetal calf serum. PHKs were iso-
lated from neonatal foreskins as described previously [27]
and cultured in Keratinocyte-SFM Medium (GibcoW, Life
Technologies™).
Total RNA extraction
Cells pellets containing 106 cells were lysed with TRIzol
reagent (Invitrogen, Belgium) for 3 minutes at room
temperature. Chloroform, 20% of total volume, was added
to the mixture which was subsequently centrifuged
(13,000 rpm) at 4°C for 15 minutes. The upper aqueous
layer containing the RNA was recovered and mixed
with an equal volume of 70% ethanol. The RNA was
further purified by RNeasy Mini Kit (Qiagen Benelux,
Netherlands) according to manufacturer’s instructions.
Concentration and purity of RNA was determined with
a NanoDrop ND1000 device (Fisher Scientific, Belgium).
Integrity of RNA samples was verified by standard de-
naturing agarose gel electrophoresis. For microarray ex-
periments, RNA quality was also assessed by an Agilent
Bioanalyzer system (Agilent, Belgium).
Gene expression profiling by microarrays
Human Genome U133 Plus 2.0 arrays (Affymetrix, CA,
USA) were used to analyze whole genome gene expres-
sion in a single hybridization, containing more than
54,000 probe sets and covering approximately 38,500
genes. Array hybridization, scanning and image analyz-
ing were done according to the manufacturer’s protocols
(Affymetrix GeneChip Expression Assay) at the VIB
Nucleomics Core Facility (www.nucleomics.be).
Three different microarray experiments were carried
out to evaluate gene expression changes following
50 μg/ml CDV treatment: experiment ‘1’ included a wide
range of treatment periods (between 2 h and 120 h) of
SiHa cells using one microarray per time point and per
condition; experiment ‘2’ consisted of SiHa cells treated
for 24 h, 48 h, and 72 h; experiment ‘3’ comprised HeLa,
HaCaT, and PHK exposed to CDV for 72 h. In thesecond and third experiments, gene expression profiling
was explored by triplicate testing.
Analysis of microarray data
Raw data were corrected for background signal using
the RMA (Robust Multi-array analysis) algorithm
(affy_1.22.0 package of BioConductor) that normalizes
the data so that different arrays can be compared to
each other and summarizes the data into expression
values [28]. The detection (Present/Absent) call gener-
ated by the Affymetrix microarray suite version 5 soft-
ware (MAS 5.0) was used to remove probe sets that
were not reliable detected in any of the microarrays
before further analysis.
Differentially expressed (DE) probe sets between CDV
treated and untreated cells were determined using a
moderated t-statistic test [LIMMA (linear models for
microarray data), BioConductor]. The Benjamini Hochberg
correction for multiple testing [p < 0.05, false discovery
rate (FDR) = 0.05] was performed [29]. Probe sets
were considered significantly DE if the absolute fold
change (FC) was > 2 and the P-value was < 0.05 (LIMMA)
after applying the Benjamini-Hochberg correction. The
resulting list of relative gene expression levels for a given
condition was designated as a data set (Additional file 1:
Figure S1).
Microarray data accession number
The entire set of microarray data is deposited in the
Gene Expression Omnibus (GEO, http://www.ncbi.nlm.
nih.gov/projects/geo) according to MIAME standards
under accession numbers GSE26748 (SiHa data) and
GSE39293 (HeLa, HaCaT, and PHKs data), respectively:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=lpivfquymowyazo&acc=GSE26748
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=lbqtpommkiccudo&acc=GSE39293
Bioinformatics analysis of differentially expressed (DE)
genes
Ingenuity Pathways Analysis (IPA, IngenuityW Systems,
Redwood City, CA, USA; http://www.ingenuity.com) ver-
sion 9 was used to perform functional, transcription factor,
and canonical pathway analysis. The IPA application re-
veals relevant pathways and biological functions by com-
paring the number of genes that participate in a given
function or pathway, relative to the total number of occur-
rences of those genes in all the pathways stored in the
IPKB (Ingenuity Pathway Knowledge Base).
Data sets with the corresponding FC and P-value were
uploaded into the IPA software. Stringent criteria, equiva-
lent to those described for the selection of DE probes, were
applied to identify DE genes. When genes were represented
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FC was used. Uncharacterized probe sets were not in-
cluded in the analysis. Networks were built by determining
all interactions among genes categorized with the func-
tional analysis.
RT-PCR analysis
To validate the microarray data, expression levels of
selected genes were determined by real-time RT-PCR
using the TaqManW Fast Universal PCR Master Mix
and TaqManW Gene Expression Assays from Applied
Biosystems (Foster City, CA, USA). Equal amounts of
total RNA isolated from CDV treated and untreated
cells were transcribed to cDNA with the First-Strand
cDNA Synthesis Kit (GE Heathcare, Little Chalfont,
UK) following manufacturer’s instructions. RT-PCR
was performed on a 7500 Fast Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) according
to manufacturer’s instructions. Relative expression
levels were calculated with the ΔΔCT method, using
β-actin as endogenous control (Applied Biosystems).
The expression of the two HPV16 oncogenes E6 and E7
in SiHa cells was also quantified with RT-PCR. The cDNA’s
were prepared as described above and RT-PCR was also
carried out under the same experimental conditions. The
following forward (F) and reverse (R) primers and probes
(P) were used: HPV16_E6_F: 5′-AGAACTGCAATGTT
TCAGGACC-3′, HPV16_E6_R: 5′-TGTATAGTTGTTTG
CAGCTCTGTGC-3′, HPV16_E6_P: (FAM) 5′-ACAGGA
GCGACCCAGA-3′, HPV16_E7_F: 5′-GCTCAGAGGAG
GAGGATGAAATAGA-3′, HPV16_E7_R: 5′-GAGTCAC
ACTTGCAACAAAAGGTT-3′, HPV16_E7_P: (FAM) 5′-
TCCGGTTCTGCTTGTCC-3′.
Metabolism study with [5-3H]-CDV
Radioactive [5-3H]-labeled CDV was used to evaluate
the metabolism in the different cell types. Cells (2 × 106
cells per 75 cm2 flask) were incubated with [5-3H]-CDV
at a final concentration of 50 μg/ml and 10 μCi per flask.
After 72 h incubation at 37°C, samples for HPLC ana-
lysis were prepared by methanol extraction as described
previously [30]. For HPLC analysis, 200 μL extract was
injected onto an anion-exchange Partisphere SAX col-
umn (dimensions: 4.6 mm × 125 mm) from Whatman
(Maidstone, UK), and separated with two phosphate
buffers (A: 5 mM and B: 0.3 M ammonium dihydrogen
phosphate; both at pH 3.5), and the following gradient
(flow: 2 ml/min): 100% A (5 min); linear gradient to
100% B (15 min); 100% B (20 min); linear gradient to
100% A (5 min) and 100% A (15 min). One minute frac-
tions of the eluate were collected, mixed with Hisafe 3
cocktail (Perkin Elmer, Waltham, MA) and analyzed for
radioactivity in a scintillation counter. The retention
times of the different CDV metabolites were: 3 min forCDVp-choline; 5 min for CDV; 15 min for CDVp; and
19 min for CDVpp.
To determine incorporation of [5-3H]-CDV into cellu-
lar nucleic acid material, the methanol-insoluble pellets
were digested in 500 μl 5 M sodium hydroxide during
24 h incubation at 37°C. Sodium hydroxide extracts were
neutralized with 500 μl 5 M hydrochloride. Nucleic acid
samples were transferred to scintillation vials, mixed
with Hisafe 3 cocktail (Perkin Elmer, Waltham, MA) and
analyzed for total radioactivity in a scintillation counter.
All conditions were performed in duplicate.
Results
Metabolism and incorporation
Since CDV has been suggested to be preferentially
converted to its active diphosphate form (CDVpp) in
HPV16+ cells [24], we investigated the metabolism of
[5-3H]-CDV in HPV+ cervical carcinoma cells com-
pared to HPV- immortalized keratinocytes and normal
keratinocytes. Following 72 h incubation with the com-
pound, CDV-phosphocholine (which is considered the
intracellular depot form of CDV) appeared to be the
most abundant metabolite while the monophosphate
form (CDVp) was the least abundant one in all four cell
types. No significant differences in the levels of the
active metabolite (CDVpp), CDV-phosphocholine or
CDV were observed between PHKs and HPV+ tumor
cells. However, lower CDVp levels were measured in PHKs
compared to HPV+ cells following 72 h incubation.
Notably, lower concentrations of CDV and of all me-
tabolites were observed in HaCaT cells, compared to
either HPV+ cells or PHKs (Table 1), suggesting that
HaCaT cells have a different uptake and/or efflux of
CDV, rather than differences in drug metabolism.
To compare the efficiency of CDV incorporation into
genomic DNA in the different cell types, we performed
an analysis of the methanol-insoluble pellets obtained
from each cell type after incubation with radiolabeled
compound for 72 h. Although the levels of intracellular
CDV metabolites were not strikingly different in PHKs
compared to immortalized keratinocytes and HPV+
tumor cells, evaluation of the methanol-insoluble frac-
tions revealed important differences between the distinct
cell types with higher amounts of CDV incorporated in
tumor cells compared to normal keratinocytes. Follow-
ing 72 h incubation, 2 pmol of CDV was found in the
methanol-insoluble fraction per million cells for PHKs
while at least 4-fold (HaCaT), 6-fold (HeLa) and 9-fold
(SiHa) higher levels were determined in the immortal-
ized keratinocytes and HPV+ tumor cells (Table 1).
These data indicate that CDVpp is more effective in
terms of inhibition of cellular DNA synthesis leading
to S-phase arrest for malignant cells than for normal
cells. The higher incorporation of CDV into cellular DNA
Table 1 CDV metabolism and incorporation
SiHa [pmol/10e6 cells] HeLa [pmol/10e6 cells] HaCaT [pmol/10e6 cells] PHKs [pmol/10e6 cells]
Methanol-soluble fraction
CDV 4.55 ± 0.03 3.20 ± 0.25 1.76 ± 0.11 4.62 ± 0.63
CDVp 2.35 ± 0.13 1.61 ± 0.04 0.38 ± 0.08 0.78 ± 0.14
CDVpp 3.50 ± 0.02 2.93 ± 0.08 1.56 ± 0.01 3.56 ± 0.28
CDVp-choline 11.90 ± 0.37 8.73 ± 0.24 2.65 ± 0.12 9.18 ± 1.34
Sum of all metabolites 22.29 ± 0.23 16.47 ± 0.06 6.34 ± 0.08 18.13 ± 2.39
Digestion of methanol- insoluble fraction
Incorporated CDV 18.39 ± 0.54 13.17 ± 1.43 8.62 ± 1.11 1.96 ± 0.71
Cells were incubated for 72 h with 10 μCi radiolabeled CDV (final concentration of 50 μg/ml) to asses metabolism and incorporation in cellular DNA. Data are the
mean ± SD of two experiments.
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mal cells is in agreement with the selectivity of this
compound for tumor cells. To investigate the conse-
quences of this differential incorporation of CDV into
cellular DNA, whole human genome gene expression
profiling was performed.
Gene expression profiling
Kinetic study of gene expression changes
First, a kinetic study was performed to assess gene ex-
pression changes in SiHa cells incubated in the presence
or absence of CDV for different times (from 2 h to
120 h). Considering the minimal changes observed up
till 24 h following CDV addition, a second kinetic was
performed that included treatment for 24 h, 48 h and
72 h. After 24 h, only 2 genes (DHRS2 and HIST1H2AC)
were downregulated, while no genes were found to be
upregulated. Venn diagrams (Figure 1A) were used to
classify the total number of genes whose expression
change was specific to or common in the comparisons
of CDV treatment for 24 h, 48 h and 72 h. The number
of differentially expressed (DE) genes increased with the
duration of CDV exposure. A total of 27 and 140 genes
were DE after, respectively, 48 h and 72 h of CDV ad-
ministration, the majority of the genes being upregulated
(17 and 108 genes after 48 h and 72 h, respectively). Out
of the 27 genes that showed an altered expression level
following 48 h of treatment with CDV, 20 showed a
similar alteration after 72 h (Figure 1A).
Comparison of gene expression profiling among different
cell types
Based on the kinetic study and taking into account the
overlap between the 48 h and 72 h data, the impact of
CDV on gene expression in different cell types was eval-
uated at 72 h post-administration of the compound. To
investigate the selectivity of CDV for HPV+ tumor cells
and whether the presence of HPV affects the response to
CDV, an HPV18+ carcinoma cell line (HeLa), an HPV-immortalized keratinocyte cell line (HaCaT), and normal
keratinocytes (PHKs) were evaluated in addition to SiHa
cells (Additional file 1: Figure S1).
A comparison of the total number of genes that were
found to be DE among the four cell types is depicted
with Venn diagrams (Figure 1B). Similarly to SiHa cells,
most of the DE genes were upregulated in HeLa, HaCaT
and PHKs. The number of genes with deregulated expres-
sion was higher in HPV- than in HPV+ cell types. The vast
majority of DE genes following CDV incubation did not
overlap between the different cell types. Only two genes
(AOX1 and CLIC3) were upregulated in all four tested cell
types. Genes with reduced expression levels common to all
four cell types were not detected (Figure 1B).
Different types of analysis (functional, upstream regu-
lator, and pathway analysis) were performed with the
four microarray data sets through the use of Ingenuity
Pathways Analysis (IPA, IngenuityW Systems). A com-
parison of the functional annotations upregulated or
downregulated following CDV treatment in the four cell
types is shown in Additional file 2: Figure S2 and a
complete list with all identified canonical pathways af-
fected by CDV is given in Additional file 3: Table S1.
The upstream regulator analysis, a novel approach to
transcription factor prediction, was used to predict acti-
vation or inhibition of transcription factors to describe
gene expression alterations in our data set (Additional
file 4: Table S2). In addition, IPA was used to generate
networks which are graphical representation of molecu-
lar relationships between different genes.
Validation of gene expression changes by RT-PCR
To validate the microarray data, the expression of selected
genes (AOX1, DHRS2, HIST1H2AC, ICAM4, MAP2K6,
and OSMR) was quantified by real time RT-PCR. Genes
that were found to be up- or downregulated by CDV in
the microarray data were confirmed by RT-PCR assay
(Figure 2A) while those that were not DE in the micro-
array data showed similar results by RT-PCR. Only a
Figure 1 Venn diagram representation of differentially expressed genes in the microarray experiments. (A) Venn diagram analysis identifying
the common and exclusively DE genes in SiHa cells treated with CDV for 24 h, 48 h, and 72 h and table listing the genes that were DE (log2 fold) at 24 h
or 48 and 72 h post-treatment. (B) Venn diagram analysis of DE genes among the four cell types following treatment with CDV for 72 h and table listing
the genes that were only up- or downregulated (log2 fold) in all four cell types, only in HPV
+ cells, or only in HPV- cells.
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level of DHRS2 in HaCaT cells. This gene was 1.9-fold
upregulated in the microarray data, which was just below
the cut-off (2-fold DE), while being 2.9-fold upregulated
in the RT-PCR assay.
Considering that HPV abrogates the functions of the
p53 and pRb tumor suppressor proteins and that CDV
treatment results in increased levels of these two pro-
teins [19], we also evaluated TP53 and RB1 mRNA levels
by RT-PCR. Similar to the microarray data, no changes
in expression levels of TP53 and RB1 were registered by
RT-PCR (Figure 2A). Thus, increased p53 and pRb pro-
teins levels following treatment with CDV reflect post-
transcriptional regulation of these genes.
CDV activates the inflammatory response by different
mechanisms in immortalized cells and PHKs
A comparison of the functional annotations affected
by CDV in either of the four cell types revealed ‘im-
mune response’ and ‘inflammatory response’ to be the
only functions upregulated in the different cell types(Figure 3). However, canonical pathway analysis showed
that the effect of CDV on immune response pathways is
different for immortalized keratinocytes and HPV+ tumor
cells compared to normal keratinocytes (Additional file 3:
Table S1). Despite the lower number of DE genes in im-
mortalized keratinocytes and HPV+ tumor cells than in
PHKs, a higher proportion of pathways related to immune
response was seen in these cells: 3/9 in SiHa, 21/53 in
HeLa, 31/57 in HaCaT, compared to 5/35 in PHKs.
Networks were then constructed with DE genes related
to inflammatory response (Additional file 5: Figure S3),
showing a distinct drug effect on this function in the dif-
ferent cell types. Pathways included in the ‘inflammatory
response’ networks showed that CDV modulated several
inflammation-associated signaling pathways in immortal-
ized cells and HPV+ tumor cells: ‘Acute Phase Response
Signaling’ in SiHa, HeLa and HaCaT cells; ‘Activation of
IRF by Cytosolic Pattern Recognition Receptors’, ‘IL-10
Signaling’, ‘IL-6 Signaling’, ‘p38 MAPK Signaling’, ‘TREM1
Signaling’, ‘Interferon Signaling’ in HeLa and HaCaT cells;
‘ILK Signaling’, ‘Oncostatin M Signaling’, and ‘Role of
Figure 2 Gene expression evaluated by real-time RT-PCR. (A) The TaqManW Fast Universal PCR Master Mix and TaqManW Gene Expression
Assays from Applied Biosystems were employed to determine expression of the following genes (with assay ID’s): AOX1 (Hs00154079_m1),
DHRS2 (Hs01061576_m1), HIST1H2AC (Hs00374312_s1), ICAM4 (Hs00169941_m1), MAP2K6 (Hs00992389_m1), OSMR (Hs00384276_m1), TP53
(Hs99999147_m1), and RB1 (Hs01078075_m1) in SiHa, HeLa, HaCaT, and PHKs following CDV treatment for 72 h. White bars represent the relative
expression values of the microarray data. Black bars represent average RT-PCR values (±SD), relative to untreated cells and normalized against
β–actin, from three independent samples. (B) Relative expression levels of HPV16 E6 and E7 in SiHa cells following treatment with CDV for
different times, relative to untreated SiHa cells and normalized against β–actin. The bars show average values (±SD) of at least three independent
experiments. An absolute 2-fold change difference was considered as biologically significant and is indicated by dashed lines in the figures.
De Schutter et al. BMC Medical Genomics 2013, 6:18 Page 7 of 17
http://www.biomedcentral.com/1755-8794/6/18RIG1-like Receptors in Antiviral Innate Immunity’ in
HeLa cells; ‘Toll-like Receptor Signaling’ in SiHa cells;
and ‘HMGB1 Signaling’, ‘IL-15 Production’, ‘IL-17 Sig-
naling’, ‘IL-8 Signaling’, ‘NF-κB Signaling’, and ‘OX40
Signaling’ in HaCaT cells (Additional file 5: Figure S3).
In contrast, only two pathways (‘Interferon Signaling’
and ‘Role of IL-17A in Psoriasis’) related to inflamma-
tory response were recognized in PHKs.
Among the DE genes involved in inflammatory response,
solely one gene (AOX1) was found to be upregulated in all
four cell types while MGLL was the only gene upregulated
in the immortalized keratinocytes and HPV+ tumor cells
(Additional file 5). Few genes [such as the adhesion mol-
ecule NEDD9 (SiHa and HeLa) and several genes involved
in interferon signaling (HaCaT)] were upregulated both in
normal keratinocytes and in one of the immortalized cells.
Increased expression of pro-inflammatory cytokines
(IL1, IL6, IL18), genes involved in cytokine-cytokine signal-
ing cascades (IL1R, IL6R, TNFAIP3, TNFAIP6, TNFSF13B,
PTX3), cell-cell adhesion (CDH1, ICAM1, FN1, ITGA2),tissue remodeling (VEGF), extracellular matrix (ECM), and
proteolysis (SERPINE1) characterized the inflammatory
response induced by CDV in immortalized keratinocytes
and HPV+ tumor cells. Also, regulators of cytokine
signaling and NF-κB activation (SPHK1, IRAK2), enzymes
involved in the synthesis of prostaglandins (PTGS1),
deubiquinating enzymes (CYLD), and members of the
G-protein coupled receptor superfamily (ADRB2) were
upregulated in these cells. In PHKs, the inflammatory
response was mainly driven by upregulation of genes
involved in interferon signaling, including IFIT1, IRF1,
OAS1, and STAT1.
Most of the DE genes in the PHKs ‘inflammatory
response’ network were not affected in the other cell
types. Moreover, some of the genes in these networks
were oppositely affected in PHKs versus immortalized
keratinocytes and HPV+ tumor cells: extracellular matrix
protein tenastatin (TNC) downregulated in PHKs and
upregulated in SiHa and HaCaT cells; topoisomerase
TOP2, lipoxygenase ALOX5, mitogen-activated protein
Figure 3 Effect of CDV exposure on functions related to inflammatory response (A), cell death (B), and cell cycle (C). The regulation
z-score predicts whether an identified biological function is activated or inhibited. Positive z-scores indicate activation of a biological function,
while negative z-scores suggest an inhibition. Absolute z-score values above 1 are considered significant. All identified functional annotations are
represented in Additional file 2: Figure S2.
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kinase PBK upregulated in PHKs and downregulated
in HaCaT cells; transforming growth factor TGFB2 and
transcriptional regulator NUPR1 upregulated in HaCaT
and downregulated in PHKs; myosin light chain kinase
MYLK upregulated in HeLa cells and downregulated
in PHKs.
Retinoid X receptor (RXR) pathways are distinctly affected
by CDV in immortalized cells and PHKs
Retinoid X receptors (RXRs) are nuclear receptors which
are ligand-regulated transcription factors that modulate
development, differentiation, and homeostasis. They
recognize target genes by binding to specific DNA rec-
ognition sequences, known as hormone response ele-
ments. RXRs are important heterodimer partners for
many nuclear receptors, including vitamin D3 receptors
(VDRs) and liver X receptors (LXRs) [31].
Activation of LXR/RXR pathways following CDV
treatment was exclusively observed in the immortalized
keratinocytes and HPV+ tumor cells (Additional file 3:
Table S1) and was associated with increased mRNA
levels of the toll-like receptor TLR4, ABC transporters
(ABCG1, ABCA1), inflammatory cytokines (IL1A, IL6,IL18), cytokine receptors (IL1R1, IL1RN, IL1R2, IL36RN),
matrix metallopeptidase (MMP9), and/or cyclooxygenase
(PTGS2). Activation of LXR/RXR pathways was also linked
to downregulation of genes involved in fatty acid bio-
synthesis such as SCD and of the E3 ubiquitin-protein
ligase (MYLIP) in HaCaT cells. Except for ARG2 that
was upregulated in HaCaT and downregulated in
PHKs, these genes were not affected in PHKs.
In contrast to HPV+ cells, activation of the VDR/RXR
signaling pathway was recorded in HaCaT and PHKs, yet
DE genes implicated in this pathway were rather differ-
ent between these two cell types. Only increased expres-
sion of cystatin CST6 (implicated in tumor suppression)
and of the dehydrogenase HSD17B2 (involved in sterol
metabolism) were common to both PHKs and HaCaT.
Rho GTPase pathways were affected by CDV exclusively
in immortalized keratinocytes and HPV+ tumor cells
Pathway analysis showed that changes in Rho GTPase
pathways were solely observed in the immortalized cells
and HPV+ tumor cells: ‘RhoGDI Signaling’ in both HPV+
cells; ‘Rac Signaling’ in SiHa cells; ‘RhoA Signaling’,
‘Regulation of Actin-based Motility by Rho’, and ‘Signal-
ing by Rho Family GTPases’ in HeLa cells; and ‘Cdc42
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upregulated by CDV that were associated with these
pathways encompassed: several members of the major
histocompatibility (HLA) complex, different receptors
(estrogen receptor ESR1, NK cell-activating receptor
NCR2, extracellular matrix receptor CD44), several regula-
tors of the Rho family of GTPases [E-cadherin (CDH1), in-
tegrin alpha-2 (ITGA2), myosin (MYL9, MYLK), the ras
GTPase-activating-like protein IQGAP2, the insulin-like
growth factor 1 IGF1, actins (ACTA2, ACGTG2, ACTC1),
the Rho GTPase binding protein CDC42EP3] and a mem-
ber of the Abelson family of nonreceptor tyrosine protein
kinases ABCL2. Only three genes (the Rho GDP dissoci-
ation inhibitor ARHGDIA, the transcription factor FOS,
and the protein kinase PRKCA) involved in Rho GTPase
pathways were downregulated by CDV in immortalized
cells. Except for MYL9 and MYLK that were oppositely
regulated in PHKs versus immortalized keratinocytes
and HPV+ tumor cells, none of these genes was DE in
normal keratinocytes after CDV exposure. Interestingly,
another Rho GDP dissociation inhibitor ARHGDIB was
upregulated in PHKs.
Specific gene expression signatures in HPV+ tumor cells
and immortalized keratinocytes treated with CDV
Four genes (GLIPR1, MAFB, MGLL, and SERPINB7)
were exclusively induced by CDV in all three immortal-
ized cells (Figure 1B). These genes are involved in cell
death (GLIPR1 and MAFB), growth of cells (SERPINB7),
differentiation (MAFB), and migration (MAFB and
MGLL). Furthermore, MGLL was associated with lipid
metabolism which plays a critical role in malignancy of
cancer cells [32] and indeed, lipid metabolism was af-
fected by CDV in HeLa and HaCaT cells (Additional
file 2: Figure S2).
Functions related to cancer encompassed the largest
number of genes (and most significant P-values) in all
tested cell types. While a significant z-score for functions
related to cancer was calculated in the immortalized
cells, functional annotations associated with malignant
transformation had a non-significant z-score in PHKs
(Additional file 2: Figure S2).
Based on DE of target genes following exposure to CDV,
activation or inhibition of transcription factors was pre-
dicted by means of upstream regulator analysis with IPA
(Additional file 4: Table S2). In SiHa cells, solely MYCN ac-
tivities showed a significant negative z-score and thus pre-
dictive of a decreased activity. Based on z-score values,
decreased activities of MYCN were determined in all three
immortalized cells although a non-significant P-value was
calculated for SiHa and HaCaT cells. Activities of the MYC
transcription factor, another member of the MYC family of
transcription factors, were predicted to be inhibited in
HeLa and HaCaT cells.Selectivity of CDV for HPV+ tumor cells: induction of
apoptosis
The functional annotation ‘apoptosis of tumor cell lines’
was activated following CDV treatment in HPV+ cells
(Figure 3). Specific sets of genes linked to cell death of
tumor cells appeared to be altered following CDV treat-
ment (Figure 4A-B). Most of these genes were only af-
fected in SiHa and/or HeLa cells but not (or reversely)
affected in PHKs. Among others, downregulation of
MDM4 and ARHGDIA and upregulation of BIK and
CYLD in SiHa cells, and upregulation of DKK3, MYLK,
PLAU, and TIMP3 in HeLa cells, were associated with
induction of cell death. Upregulation of CRYAB in HPV+
cells was linked to both decreased apoptosis and de-
creased growth of cells, reflecting the diverse effects de-
scribed for this gene. The association of DE genes with
pathways related to apoptosis signaling was highlighted
in the cell death networks built for the malignant cells
(Figure 4A-B).
In contrast to HPV+ cells, HaCaT showed decreased
‘cell death of tumor cells’ and ‘cell viability of tumor cells
lines’ following CDV treatment (Figure 3). Pathways af-
fected by CDV identified in the cell death network built
for HaCaT were different from those found in HPV+
cells and included ‘p53 Signaling’, ‘Aryl Hydrocarbon Re-
ceptor Signaling’, ‘HGF Signaling’, and ‘JAK/STAT Sig-
naling’ (Figure 4C).
CDV affects cell cycle regulation differently in
immortalized keratinocytes versus normal keratinocytes
Functional analysis suggested distinct effects of CDV on
cell cycle in PHKs and HaCaT, while no functional anno-
tations associated with cell cycle were identified in HPV+
cells (Figure 3). Similarly, pathways related to cell cycle
control were mainly identified in HaCaT and PHKs
(Additional file 3: Table S1). Although the activities of
the transcription factor p53 were activated in HeLa and
HaCaT (Additional file 4: Table S2), the ‘p53 Signaling’
pathway was affected in HaCaT and normal keratinocytes
but not in HPV+ cells, with TP63 (member of the p53
transcription factor family) downregulated in PHKs and
upregulated in HaCaT.
Distinct sets of genes involved in pathways related to
‘cell cycle’ and ‘DNA replication, recombination, and re-
pair’ were altered in HaCaT and PHKs. Several cyclins
and cyclin-dependent kinases (CDKs) that play a key
role in cell cycle control were differentially modulated
by CDV in HaCaT and PHKs: CCNA2 and CCNB1 were
downregulated in HaCaT and upregulated in PHKs;
CDK1, CDK6, and CCNE2 were upregulated in PHKs, but
not in HaCaT.
Prediction of transcription factor activities also
showed significant differences between PHKs and HaCaT
(Additional file 4: Table S2). Notably, SMARCB1 (that
Figure 4 (See legend on next page.)
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Figure 4 Networks of ‘cell death of tumor cell lines’ function and corresponding transcripts. Networks were constructed with IPA software
using genes DE and involved in ‘cell death of tumor cell lines’ following CDV treatment of (A) SiHa, (B) HeLa, or (C) HaCaT cells. A network is a
graphical representation of the molecular relationships between molecules (nodes). The biological relationship between two nodes is represented
as an edge connecting two nodes. All edges are supported by information from the literature stored in the Ingenuity Pathways Knowledge Base.
The intensity of the node color indicates the degree of up-regulation (red) or down-regulation (green) following CDV treatment. Canonical
pathways identified by IPA in the networks are shown in blue. Except for DAB2, SERPINI1, CFH, and NEDD9 in SiHa; NEDD9, DKK1, DDX58, CDF15,
DUSP4, CASP1, IGFBP3, F2R, SLC7A11, and ASNS in HeLa; XAF1, TRIM21, USP18, TNFSF13B, STAT4, GLRX, DDX58, GEM, TBX3, BMP2, TUBA1A, STAT1, CTGF,
IL8, GDF15, CYP1B1, PTHLH, THBS1, CASP1, IL11, CLU, and CTSL2 in HaCaT; no changes in expression for genes included in the cell death networks
built for the immortalized cells were observed in PHKs. Notably, BMP2 (SiHa); MYLK (HeLa); and NUPR1, NUF2, SPC25, BUB1, TOP2A, DEPC1, CCNB1,
PBK, TGFB2, TP63, ABCG2, CCNA2, MKI67, SSPN, NRG1, MAP3K8, and ALOX5 (HaCaT) were inversely regulated in PHKs.
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tions were activated in HaCaT, but inhibited in PHKs.
TBX2 [that suppresses the expression of CDK inhibitors
such as p15 and p21 and destabilizes p53 by suppressing
expression of ARF (an inhibitor of MDM2)] predicted
functions were inhibited in HaCaT but activated in PHKs.
Other transcription factors appeared to be either activated
or inhibited exclusively in HaCaT or PHKs, but not
in both. Thus, the activities of the tumor suppressor
SMARC4A (that mediates ATP-dependent chromatin
remodeling processes) and of the histone demethylase
KDM5B (that associates with and contributes to the re-
pression of E2f-target genes during senescence) were
exclusively activated in HaCaT cells. Furthermore, by
inhibiting CDKs, the tumor suppressor p16 (CDKN2A),
whose predicted activities were upregulated in HaCaT
cells, triggers the G1-S checkpoint that is often consid-
ered to be crucial for inducing a senescence-like growth
arrest. In line with growth arrest in HaCaT cells, are the
decreased predicted activities of the E2f transcription
factor (regulator of expression of genes such as cyclins,
CDKs, components of the pre-replication, and DNA
synthesis genes) and the increased predicted activities
of the chromatin associated protein HMGB1 (that facil-
itates p53 phosphorylation after to genotoxic stress)
and of NFκB (a pleiotropic transcription factor that can
be activated by DNA damage).
The occurrence of cell cycle arrest in HaCaT was fur-
ther evidenced by upregulation of CDKN1A (p21) and
downregulation of CCNA2, CCNB1, TOPA2, SKP2,
HDAC8, and PPM1L, in contrast to PHKs (Additional
file 6: Table S3).
Specific gene expression signatures in PHKs exposed to CDV
Activation of metabolic pathways
Whereas immortalized keratinocytes and HPV+ tumor
cells were found to have more alterations in immune re-
sponse pathways compared to the PHKs, seventeen differ-
ent pathways (out of 35) linked to metabolism were
seen in PHKs versus only one (SiHa), two (HaCaT)
and three (HeLa) in CDV-treated immortalized cells
(Additional file 3: Table S1).DNA damage response and survival of epithelial cells
Pathways related to DNA repair (‘ATM Signaling’ and
‘DNA Double-Strand Break Repair by Homologous
Recombination’) were exclusively identified in PHKs,
suggesting activation of DNA repair mechanisms fol-
lowing CDV-induced DNA damage. Several cell div-
ision cycle (CDC) homologs (such as CDC2, CDC6,
CDC7, CDC23, and CDC25A), that play important roles in
cell cycle transition and DNA replication (Additional file 6:
Table S3), were exclusively upregulated in PHKs. In
contrast, CDC25C was found downregulated in HaCaT.
Expression of genes encoding for proteins involved in
DNA repair and checkpoint control (including ANAPC7,
BRCA1, CDT1, CKS2, EME1, GEN1, KAT2B, KIF11,
MDM2, NBN, ORC6, PCNA, RAD51, and RFC3) were
solely upregulated in PHKs (Additional file 6: Table S3).
Importantly, functional analysis revealed a decrease
(z-score < 1) of ‘cell death of epithelial cells’ follow-
ing CDV treatment of PHKs, in contrast to increased
(z-score > 1) ‘cell death of tumor cell lines’ in SiHa and
HeLa (Figure 3). The upregulation of anti-apoptotic
genes (such as BIRC5) in PHKs suggested a successful
response to DNA damage.
Discussion
In this study, the basis for selectivity of CDV for HPV+
tumor cells could be demonstrated based on analysis of
drug incorporation into genomic DNA as well as gene
expression profiling in HPV+ tumor cells, HPV- immor-
talized keratinocytes and normal keratinocytes. Bioinfor-
matics analysis of microarray data highlighted distinct
responses to CDV exposure in PHKs compared to HPV+
cervical carcinoma cells, on one hand, and to HPV- im-
mortalized keratinocytes, on the other hand.
Our findings indicate that the selectivity of CDV for
HPV-transformed cells is based on differences in re-
sponse to DNA damage, replication rate and CDV in-
corporation into cellular DNA between immortalized
cells and PHKs, rather than a specific effect of the drug
on the viral oncogenes. However, the presence of E6 and
E7 indirectly contributes to the efficacy and selectivity of
CDV, because viral oncoproteins deregulate cell cycle,
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favoring the antiproliferative effects of CDV.
Gene expression profiling of CDV-treated HaCaT and
PHKs revealed specific signatures that clearly explain a
differential outcome in both cell types following drug
exposure (Figure 5). Except for CYP1B1 and THBS1,
complete different sets of genes in pathways related to
‘cell cycle’ and ‘DNA replication, recombination, and re-
pair’ were modulated following CDV exposure of HaCaT
and PHKs, supporting a differential effect on ‘cell cycle’
functions in immortalized and normal keratinocytes.
Interestingly, mRNA levels of many genes involved in
these functions were oppositely regulated by CDV in
PHKs and in HaCaT cells or exclusively affected in
one of the cell types. HaCaT cells respond to CDV
by attempting cell cycle regulation which fails because
of the inability of these cells to repair DNA damage
(Figure 5). This is further sustained by CDV triggeringFigure 5 Differential responses to CDV treatment of HPV+ tumor cells an
selectivity mechanism. Incorporation of CDV during DNA synthesis leads to D
elicited depending on the cell type and p53 status. Normal keratinocytes activa
homologous recombination, leading to genomic stability and cell survival. Des
activate a DNA repair mechanism, while HPV+ tumor cells lack cell cycle regula
DNA damage leads to genomic instability and activation of apoptosis in these
are cited, with their relevant genes marked in red when upregulated and in grof ‘p53 Signaling’ in HaCaT and normal keratinocytes
but not in cervical cancer cells. Also, the prediction of
transcription factor activities points to cell cycle arrest
in HaCaT but not in PHKs.
Specific signatures identified in CDV-treated PHKs
point to cell cycle regulation and activation of DNA
double-strand breaks (DSBs) repair mechanism (‘ATM
Signaling’ and ‘DNA Double-Strand Break Repair by
Homologous Recombination’), suggesting that CDV can
generate DSBs. Homologous recombination (HR) is a
conservative process that tends to restore the original
DNA sequence at the site of damage. Expression of
genes involved in DNA repair by non-homologous end-
joining (NHEJ) was not seen in CDV-treated PHKs. This
points to a non-mutagenic CDV effect as NHEJ can be
mutagenic because it mediates repair by directly ligating
the ends of DSBs together, in contrast to HR that is con-
sidered a faithful DNA repair process [33]. Since CDVd immortalized keratinocytes versus PHKs and proposed CDV
NA damage signaling and elevated p53 levels. Distinct responses are
te cell cycle regulation mechanisms that allow DNA repair by means of
pite blocking cell cycle progression, HPV- immortalized cells are not able to
tion and DNA repair due to E6 and E7 oncoproteins. The inability to repair
cells. Altered cell cycle regulation and/or DNA damage repair pathways
een when downregulated.
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[19,20], and CDVpp, an analogue of deoxycytidine-
triphosphate, can be incorporated into cellular DNA,
this drug can cause potentially lethal chromosomal
DSBs during DNA replication.
In contrast to normal cells that possess an arsenal of
repair pathways and cell cycle checkpoints to detect and
repair DNA damage, cancer cells as well as immortalized
keratinocytes have a significantly reduced set of DNA
repair pathways for survival, which can be targeted to
develop improved treatment strategies [34]. Differences
in the response of normal cells and cancer cells to DNA
damaging agents also explain the mechanisms by which
the nucleoside analogue ganciclovir induces cell death in
tumor cells genetically modified to express the herpes
simplex virus thymidine kinase gene [35,36].
Here, we identified DE genes linked to cell death and
confirmed at the gene expression level apoptosis induc-
tion by CDV [19,21]. It should be noted that apoptosis
induction, accumulation of the cells in the S-phase, in-
creased protein levels of the tumor suppressor proteins
p53 and pRb, and decreased cell viability were evidenced
following exposure of tumor cells to CDV for 4 to 5 days
[19,20], indicating that cells need to accumulate suffi-
cient drug-induced stress before apoptosis takes place.
Distinct sets of genes linked to cell death were altered
following 72 h CDV treatment of SiHa and HeLa cells,
suggesting that although CDV treatment leads to apop-
tosis in malignant cells, different cells may respond to
CDV by modulating distinct sets of genes, most likely
reflecting variations in the genetic background between
tumor cells. Considering the DE genes involved in cell
cycle control and cell death in HaCaT, it can be assumed
that apoptosis will be triggered at a later time point than
in HPV+ cells.
HPV+ cells, that are more susceptible to the anti-
proliferative effects of CDV than HPV- immortalized
keratinocytes and normal keratinocytes [18], divide very
rapidly, present a high genomic instability and are de-
fective in cell cycle control and DNA repair mechanisms
due to the expression of E6 and E7 oncoproteins. Thus,
CDV treatment of cervical cancer cells may result in sig-
nificant DNA damage during the S-phase that should be
responsible for induction of p53 and apoptosis [19,20].
Some reports claimed that CDV could specifically
affect mRNA levels of E6 and E7 [21,37]. Abdulkarim
and colleagues found decreased E6 and E7 mRNA levels
and reduced protein expression in HPV18 positive cells
[21]. However, we were unable to detect E6 protein
levels in cervical carcinoma cells, largely due to low en-
dogenous levels of E6, as well as poor quality of available
anti-E6 antibodies, in agreement with several reports
[38-41]. On the other hand, we did not find a significant
alteration in E6 and E7 mRNA levels by quantitativeRT-PCR following treatment with CDV at 50 μg/ml
for 1- to 7 days (Figure 2B). The elevated p53 and
pRb protein levels (reported by [19,21]) cannot be at-
tributed to increased mRNA expression of these
genes according to our microarray and RT-PCR data.
It appears that the higher p53 protein levels are the
consequence of the DNA damage response following
CDV treatment that affects the expression of regula-
tors of p53 (such as MDM2, MDM4, and CDKN1A)
resulting in a rapid stabilization of p53 via blocking
of its degradation. This is in agreement with previous
reports of post-transcriptional regulation of these genes
[42], showing a rapid increase in p53 protein concen-
tration without de novo transcription which is par-
ticularly advantageous in cells with severely damaged
genomes [43].
MDM2 and MDM4 are considered the main cellular
antagonist of p53 by limiting its functions [44]. MDM4,
that inhibits p53 by binding its transcriptional activa-
tion domain [45], was downregulated in CDV-treated
SiHa cells while MDM2 was upregulated in CDV-
exposed PHKs. Thus, in PHKs, MDM2 is expected to
ubiquitinate p53 and mediate its degradation by nuclear
and cytoplasmatic proteasomes. In contrast, in CDV-
exposed malignant cells, as a consequence of DNA dam-
age accumulation, stabilization of p53 and induction of
several pro-apoptotic genes (such as BIK, CYLD, DKK3,
PLAU, and TIMP3) take place. Activation of BIK through
transcriptional pathways (dependent on factors such as
E2f and p53 or by epigenetic regulating mechanisms) was
described following treatment with anti-cancer drugs
[46], and upregulation of BIK is considered as an inter-
ventional approach to treat some tumors [47]. The tumor
suppressor CYLD encodes for a deubiquitinase that plays
a critical role in the regulation of NF-κB and activation
of caspase-8, its activation being regarded as a thera-
peutic target in the treatment of cancers [48]. The tumor
suppressor DKK3 (RIG) induces apoptosis through mito-
chondrial pathways in human colon cancer [49] and pro-
apoptotic actions of PLAU in tumor cells have also been
described [50]. The tissue inhibitor of metalloproteinases
TIMP3 promotes apoptosis involving stabilization of cell
death receptors and activation of caspase-8 [51].
Pro-apoptotic activities have been described for GLIPR1
and MAFB that were upregulated in immortalized
keratinocytes and HPV+ tumor cells. GLIPR1 was
shown to induce apoptosis in prostate cancer [52], and
to promote MYC ubiquitination and degradation lead-
ing to suppression of cancer development [53]. In line
with this report, not only upregulation of GLIPR1 but
also downregulation of the predicted activities of MYC
family members were observed in immortalized cells.
Maf proteins were shown to possess tumor suppressor
activities through induction of expression of the cell-cycle
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hibition of MYB [55,56] or induction of p53 transcription
[57]. MYCN together with MYB were shown to be in-
volved in a reciprocal regulatory loop promoting survival/
proliferation of neuroblastoma cells [58,59]. Both transcrip-
tion factors are considered potential specific targets for
cancer therapy and downregulation of MYCN expression
by treatment with antisense or by retinoid acids decreases
proliferation of neuroblastoma cells [60]. Several miRNAs,
including miR-17-92, are also known to be regulated by
MYCN [61], which showed reduced predicted activities in
HeLa. MYCN expression was found to be inversely corre-
lated with DKK3 expression [62], which is in line with our
HeLa data. Although CDV did not affect MYCN expres-
sion, decreased predicted activities of this proto-oncogene
support the antiproliferative effects of CDV and apoptosis
induction. Activities of MYC members were also reported
to be altered by a few conventional cytotoxic drugs that
target microtubules, topoisomerases, or DNA, RNA and
protein synthesis [63].
Several cyclins and CDKs were differentially modu-
lated by CDV in HPV- cells (Figure 5). Increased tran-
scription of genes required for cell cycle progression
(CCNA2 and CCNB1) suggests that pRb can be phos-
phorylated in PHKs leading to release of E2f. Further-
more, cell cycle progression appeared to be blocked in
HaCaT cells as evidenced by upregulation of CDKN1A
(p21) that blocks the activity of cyclin-CDK2/4 com-
plexes and GADD45A, whose transcript levels are in-
creased following stressful growth arrest by treatment
with DNA-damaging agents. As a consequence of the in-
creased expression of CDKN1A, the complexes cyclinD-
CDK4/6 and cyclinE-CDK2 are not activated and pRb
cannot be phosphorylated in order to release E2f.
Only two genes (AOX1 and CLIC3) were common to
all four cell types. Altered expression of CLIC3 following
CDV exposure was not associated with any of the func-
tions or pathways modulated by CDV. In contrast,
AOX1 was linked to inflammatory response, the only
common function found activated in all cell types. How-
ever, distinct pathways linked to inflammatory response
were affected by CDV in immortalized keratinocytes and
HPV+ tumor cells versus PHKs. Importantly, ‘Acute
Phase Response Signaling’, a rapid inflammatory re-
sponse using non-specific defense mechanisms that
provides protection not only against microorganisms
but also to tissue injury, neoplastic growth or immuno-
logical disorders [64], was exclusively identified in
SiHa, HeLa and HaCaT cells. Induction of DNA dam-
age by CDV in immortalized cells was associated with
acute phase response signaling which is in agreement
with data showing that DNA damage leads to an
upregulation of immunostimulatory surface ligands and
to an increased secretion of pro-inflammatory cytokines insenescent cells [65]. This may result in the activation of
acute response signaling in CDV-exposed immortalized
cells that may be important in vivo for clearance of the sen-
escent cells. Considering the number of pathways linked to
immune response identified in the CDV-treated immortal-
ized cells, it can be inferred that the inflammatory response
plays a crucial role in the response of tumor cells to CDV
and that activation of the inflammatory response can be
regarded as a cellular reaction to CDV-induced stress.
LXRs play a key role in cholesterol transport by in-
ducing the expression of ATP-binding cassette (ABC)
transporters involved in cholesterol efflux. These nuclear
receptors also control diverse pathways implicated in de-
velopment, reproduction, metabolism, immunity and in-
flammation. Recent insights into LXR signaling revealed
that targeting activation of the LXR pathway harbor
promises for the management of metabolic disorders,
chronic inflammatory diseases, cancer, and neurodegen-
erative diseases [66,67]. Therefore, activation of LXR/
RXR by CDV in immortalized cells might be an import-
ant mediator in the inflammatory response induced by
CDV in these cells.
Also, Rho GTPase pathways were exclusively identified
in immortalized keratinocytes and HPV+ tumor cells.
Rho GTPase proteins (RhoA-C, Rac1, and Cdc42) func-
tion as molecular switches in a variety of signaling path-
ways following stimulation of cell surface receptors and
regulate several biological processes, including cell cycle
control, epithelial cell polarity, cell migration, cell sur-
vival and angiogenesis [68]. Modulation of Rho GTPase
pathways by CDV identified in our microarray data is
consistent with a previous report that demonstrated
the efficacy of CDV in disrupting invasion of HeLa
cells by decreasing CXCR4 expression and inhibiting
Rho/ROCK activation [23]. RhoGDP dissociation inhib-
itors (RhoGDIs) are considered antiapoptotic molecules
[69], and different therapeutic strategies that target
RhoGDIs have previously been proposed [70]. Thus,
modulation of the RhoGDI and Rac signaling pathways
by CDV may be important in induction of cell death
as evidenced by downregulation of ARHGDIA (one of
the RhoGDIs) in SiHa cells.
Conclusion
In summary, cell cycle checkpoint control and DNA
damage repair occur only in PHKs following CDV
treatment. HPV+ cells are more susceptible to the
antiproliferative action of CDV because they are com-
pletely unable to respond to CDV-induced stress while
HaCaT cells still can respond via induction of several sig-
naling pathways but they lack proper cell cycle check-
point and DNA repairing mechanisms. Furthermore,
gene expression profiling allowed the identification of
several pathways and functions induced or repressed
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compared to HPV+ and/or HPV- cells, including Rho
GTPase pathways and ‘acute phase response’ exclusively
activated in immortalized cells. Our data also have impli-
cations for the use of CDV in combination with standard
therapy for the treatment of cancer cells that rapidly div-
ide and that show a defect in DNA repairing mecha-
nisms. CDV-induced DNA damage will preferentially
accumulate in the tumor cells resulting in S-phase arrest
and cell death. Moreover, our findings help to explain the
selective effect of CDV which has been clearly docu-
mented in several case reports and phase II/III clinical
studies [11,14-16]. CDV has been used mostly topically
to treat HPV-associated diseases showing a selective
antiproliferative effect against HPV lesions without being
associated with local side-effects on neighboring normal
epithelial cells.
The present findings may lay the scientific basis for fur-
ther studies on functions and pathways found to be differ-
entially affected by CDV in immortalized keratinocytes and
HPV+ tumor cells versus normal keratinocytes. Further-
more, this detailed microarray analysis generated a source
of novel molecular targets for the treatment of HPV-
associated diseases and potentially of non-HPV neoplasias.
Our data revealed not only interactions between genes that
illustrate useful pathways for new therapeutic targets but
also for understanding the mechanism of selectivity of
CDV. Additional combined genomic and proteomic
studies are required to reveal in even more detail the
precise mode of action of CDV and related acyclic nu-
cleoside phosphonates as double-acting (antiviral and
antiproliferative) drugs.Additional files
Additional file 1: Normalization, filtering, and analysis of microarray
data derived from CDV treated and untreated cells. Flow chart of the
microarray experiments that was applied to obtain our data sets.
Additional file 2: Functional annotations upregulated or
downregulated within functional categories following CDV treatment
in different cell types. For the functional analysis, categories associated with
unrelated cell types and with irrelevant diseases were omitted. The criteria for
selection of functional annotations were based on z-score and statistical
significance (P-value < 0.05). The regulation z-score predicts whether an
identified biological function is activated or inhibited. Positive z-scores
indicate activation of a biological function, while negative z-scores suggest
an inhibition. Absolute z-score values above 1 are considered significant.
Additional file 3: Canonical pathway analysis. Canonical pathway
analysis of changes in gene expression following incubation of SiHa, HeLa,
HaCaT, and PHKs with CDV for 72 h. The significance of the associations
between the genes from the data sets and the canonical pathways were
determined based on two parameters: (i) P-value, calculated by the Fischer’s
exact test, that determines the probability that there is an association
between the genes in the data set and the canonical pathway that cannot
be explained by chance alone and (ii) by the ratio of the number of genes
from the data set in a given pathway divided by the total number of
molecules in the given canonical pathway. P-values < 0.05 were considered
statistically significant. Pathways marked in black in the PHKs data representthe pathways that were exclusively identified in these cells, while pathways
marked in grey represent the pathways that were shared among SiHa, HeLa
cells and/or HaCaT cells.
Additional file 4: Prediction of transcription factor activities in the
different cell types. The activity of the transcription factors was evaluated
by P-value and regulation z-score whose calculation is based on relationships
with their target genes. The relationships represent experimentally observed
gene expression or transcription events associated with a direction of change
that result in activation of inhibition (as derived from the literature compiled
in the IPKB). The z-score predicts the identified transcription factors to be
activated (positive z-score) or inhibited (negative z-score). Only upstream
regulators that showed an absolute z-score > 2 in at least one of the four cell
types are represented. P-values <0.05 were considered significant.
Additional file 5: Inflammatory response networks. Networks were
constructed with IPA software using genes DE and involved in
‘inflammatory response’ following CDV treatment of (A) SiHa, (B) HeLa,
(C) HaCaT, or (D) PHKs.
Additional file 6: Effect of CDV on ‘cell cycle’ and ‘DNA replication,
recombination, and repair’ in HPV- cells. Genes modulated by CDV in
HaCaT and/or PHKs that are involved in pathways related to ‘cell cycle’
and ‘DNA replication, recombination, and repair’.
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